ALT5 Sigma (AIFC) Competitors

$0.80 -0.09 (-10.37%)

As of 05/26/2026 04:00 PM Eastern

AIFC vs. OCGN, FULC, EPRX, ZURA, and AUTL

Should you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Ocugen (OCGN), Fulcrum Therapeutics (FULC), Eupraxia Pharmaceuticals (EPRX), Zura Bio (ZURA), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

How does ALT5 Sigma compare to Ocugen?

Ocugen (NASDAQ:OCGN) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Ocugen has a net margin of -1,192.18% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Ocugen has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	101.59	-$67.85M	-$0.24	N/A
ALT5 Sigma	$24.70M	4.53	-$344.51M	N/A	N/A

Ocugen has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Ocugen had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 1 mentions for Ocugen and 0 mentions for ALT5 Sigma. Ocugen's average media sentiment score of 0.59 beat ALT5 Sigma's score of 0.00 indicating that Ocugen is being referred to more favorably in the media.

Company	Overall Sentiment
Ocugen	Positive
ALT5 Sigma	Neutral

Ocugen currently has a consensus price target of $9.75, suggesting a potential upside of 627.61%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts plainly believe Ocugen is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.3% of Ocugen shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ocugen beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Fulcrum Therapeutics has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Fulcrum Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Fulcrum Therapeutics' return on equity of -27.80% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Fulcrum Therapeutics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A
ALT5 Sigma	$24.70M	4.53	-$344.51M	N/A	N/A

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 1 mentions for Fulcrum Therapeutics and 0 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.00 beat Fulcrum Therapeutics' score of -0.50 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Negative
ALT5 Sigma	Neutral

Fulcrum Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 181.07%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Fulcrum Therapeutics beats ALT5 Sigma on 11 of the 13 factors compared between the two stocks.

How does ALT5 Sigma compare to Eupraxia Pharmaceuticals?

ALT5 Sigma (NASDAQ:AIFC) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Eupraxia Pharmaceuticals has a consensus price target of $18.33, indicating a potential upside of 143.47%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Eupraxia Pharmaceuticals and 0 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.00 beat Eupraxia Pharmaceuticals' score of -0.61 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Eupraxia Pharmaceuticals	Negative

6.3% of ALT5 Sigma shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	4.53	-$344.51M	N/A	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Summary

Eupraxia Pharmaceuticals beats ALT5 Sigma on 8 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Zura Bio?

ALT5 Sigma (NASDAQ:AIFC) and Zura Bio (NASDAQ:ZURA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Zura Bio had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Zura Bio and 0 mentions for ALT5 Sigma. Zura Bio's average media sentiment score of 0.05 beat ALT5 Sigma's score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Zura Bio	Neutral

Zura Bio has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	4.53	-$344.51M	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Zura Bio has a consensus target price of $10.75, indicating a potential upside of 155.34%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 22.1% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ALT5 Sigma has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Zura Bio has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Zura Bio's return on equity of -55.74% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Zura Bio	N/A	-55.74%	-48.07%

Summary

Zura Bio beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Autolus Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Autolus Therapeutics has a net margin of -311.98% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

In the previous week, Autolus Therapeutics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 1 mentions for Autolus Therapeutics and 0 mentions for ALT5 Sigma. Autolus Therapeutics' average media sentiment score of 0.56 beat ALT5 Sigma's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Autolus Therapeutics	Positive

Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 420.83%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

ALT5 Sigma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Autolus Therapeutics has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.70M	4.53	-$344.51M	N/A	N/A
Autolus Therapeutics	$92.62M	4.83	-$287.53M	-$1.09	N/A

Summary

Autolus Therapeutics beats ALT5 Sigma on 14 of the 15 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFC vs. The Competition

Export

Metric	ALT5 Sigma	FIN Industry	Finance Sector	NASDAQ Exchange
Market Cap	$124.90M	$7.08B	$13.61B	$12.34B
Dividend Yield	N/A	5.78%	5.81%	5.28%
P/E Ratio	N/A	90.33	23.92	25.81
Price / Sales	4.53	9.76	150.21	71.83
Price / Cash	N/A	68.84	20.16	56.67
Price / Book	0.13	2.74	2.16	7.17
Net Income	-$344.51M	$306.51M	$1.13B	$336.99M
7 Day Performance	-4.80%	0.29%	0.72%	2.87%
1 Month Performance	-5.81%	-1.79%	0.38%	3.16%
1 Year Performance	-91.06%	14.79%	11.58%	35.93%

ALT5 Sigma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFC ALT5 Sigma	0.0933 of 5 stars	$0.80 -10.4%	N/A	-91.0%	$124.90M	$24.70M	N/A	170
OCGN Ocugen	2.1051 of 5 stars	$1.47 flat	$9.75 +563.3%	+44.0%	$497.62M	$4.41M	N/A	80
FULC Fulcrum Therapeutics	1.6113 of 5 stars	$7.25 +4.2%	$19.00 +162.1%	+5.0%	$483.07M	$80M	N/A	100
EPRX Eupraxia Pharmaceuticals	2.2269 of 5 stars	$7.55 -0.8%	$15.00 +98.7%	+94.6%	$456.25M	N/A	N/A	29	Gap Up
ZURA Zura Bio	2.2048 of 5 stars	$4.80 +1.1%	$10.75 +124.0%	+312.7%	$455.42M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFC) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALT5 Sigma (AIFC) Competitors

AIFC vs. OCGN, FULC, EPRX, ZURA, and AUTL

How does ALT5 Sigma compare to Ocugen?

Summary

How does ALT5 Sigma compare to Fulcrum Therapeutics?

Summary

How does ALT5 Sigma compare to Eupraxia Pharmaceuticals?

Summary

How does ALT5 Sigma compare to Zura Bio?

Summary

How does ALT5 Sigma compare to Autolus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALT5 Sigma (AIFC) Competitors

AIFC vs. OCGN, FULC, EPRX, ZURA, and AUTL

How does ALT5 Sigma compare to Ocugen?

Is OCGN or AIFC more profitable?

Which has higher valuation and earnings, OCGN or AIFC?

Which has more volatility & risk, OCGN or AIFC?

Does the media favor OCGN or AIFC?

Do analysts prefer OCGN or AIFC?

Do institutionals & insiders hold more shares of OCGN or AIFC?

Summary

How does ALT5 Sigma compare to Fulcrum Therapeutics?

Which has more volatility and risk, FULC or AIFC?

Is FULC or AIFC more profitable?

Which has stronger valuation & earnings, FULC or AIFC?

Does the media favor FULC or AIFC?

Do analysts recommend FULC or AIFC?

Do institutionals & insiders believe in FULC or AIFC?

Summary

How does ALT5 Sigma compare to Eupraxia Pharmaceuticals?

Is AIFC or EPRX more profitable?

Do analysts rate AIFC or EPRX?

Which has more risk and volatility, AIFC or EPRX?

Does the media refer more to AIFC or EPRX?

Do insiders and institutionals hold more shares of AIFC or EPRX?

Which has higher valuation and earnings, AIFC or EPRX?

Summary

How does ALT5 Sigma compare to Zura Bio?

Does the media refer more to AIFC or ZURA?

Which has stronger earnings and valuation, AIFC or ZURA?

Do analysts prefer AIFC or ZURA?

Do insiders and institutionals have more ownership in AIFC or ZURA?

Which has more risk & volatility, AIFC or ZURA?

Is AIFC or ZURA more profitable?

Summary

How does ALT5 Sigma compare to Autolus Therapeutics?

Is AIFC or AUTL more profitable?

Does the media prefer AIFC or AUTL?

Do analysts recommend AIFC or AUTL?

Which has more risk & volatility, AIFC or AUTL?

Do insiders & institutionals believe in AIFC or AUTL?

Which has preferable earnings & valuation, AIFC or AUTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools